Daihan Pharmaceutical Co.Ltd (023910) — Capital Reinvestment Ratio
Daihan Pharmaceutical Co.Ltd (023910) has a Capital Reinvestment Ratio of 1.14x as of September 2025, meaning it reinvests 1% of its operating cash flow (₩9.47 Billion) in capital expenditures (₩10.79 Billion). See 023910 net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Daihan Pharmaceutical Co.Ltd Capital Reinvestment Ratio (2014–2024)
This chart tracks Daihan Pharmaceutical Co.Ltd's Capital Reinvestment Ratio across 11 annual periods. Check Daihan Pharmaceutical Co.Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Daihan Pharmaceutical Co.Ltd (2014–2024)
Year-by-year Capital Reinvestment Ratio for Daihan Pharmaceutical Co.Ltd from 2014 to 2024. For live market cap and broader valuation context, see Daihan Pharmaceutical Co.Ltd market cap and net worth.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.44x | ₩35.64 Billion | ₩15.80 Billion | ▼ -19.0% |
| 2023 | 0.55x | ₩38.86 Billion | ₩21.28 Billion | ▲ +84.2% |
| 2022 | 0.30x | ₩29.00 Billion | ₩8.62 Billion | ▲ +1.9% |
| 2021 | 0.29x | ₩40.62 Billion | ₩11.85 Billion | ▲ +83.0% |
| 2020 | 0.16x | ₩33.63 Billion | ₩5.36 Billion | ▼ -67.5% |
| 2019 | 0.49x | ₩35.26 Billion | ₩17.30 Billion | ▼ -52.8% |
| 2018 | 1.04x | ₩44.94 Billion | ₩46.69 Billion | ▲ +1.0% |
| 2017 | 1.03x | ₩20.45 Billion | ₩21.05 Billion | ▲ +31.2% |
| 2016 | 0.78x | ₩27.92 Billion | ₩21.90 Billion | ▲ +255.8% |
| 2015 | 0.22x | ₩17.98 Billion | ₩3.96 Billion | ▼ -80.0% |
| 2014 | 1.10x | ₩9.48 Billion | ₩10.47 Billion | — |